MedPath

Evaluation of pathophysiology of cancer based on HLA and APRs.

Not Applicable
Conditions
Esophageal cancer Gastric cancer Colorectal cancer Liver cancer Pancreatic cancer Gallbladder and bili duct cancer Breast cancer Lung cancer
Registration Number
JPRN-UMIN000037478
Lead Sponsor
Japan cancer treatment and behavior study group (JCTB)
Brief Summary

The frequencies of HLA A33, B44, Cw3, DR6, DR8, DR9 and DQ4 antigens were lower in total; therefore, these antigens may act as defensive factors of carcinogenesis.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
967
Inclusion Criteria

Not provided

Exclusion Criteria

not particular

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath